Trevi Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Trevi Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $18.91 million for the year ending 2025.

  • Trevi Therapeutics, Inc. showed a decrease of -44.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Trevi Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
  • XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 8 years of available data (2018 to 2025), Trevi Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 162.6%.
  • Historical annual values: Fiscal year 2025: $18.91 million | Fiscal year 2024: $34.10 million | Fiscal year 2023: $32.40 million | Fiscal year 2022: $12.59 million | Fiscal year 2021: $36.83 million | Fiscal year 2020: $45.00 million | Fiscal year 2019: $57.31 million | Fiscal year 2018: $7.20 million.
  • Data sourced from SEC EDGAR public filings as of June 24, 2026.

Last verified: